X
56.85
0.16 (0.28%)
| Penutupan Terdahulu | 56.69 |
| Buka | 56.00 |
| Jumlah Dagangan | 874,208 |
| Purata Dagangan (3B) | 1,426,608 |
| Modal Pasaran | 5,425,033,728 |
| Harga / Jualan (P/S) | 598.74 |
| Harga / Buku (P/B) | 9.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| Margin Operasi (TTM) | -969.84% |
| EPS Cair (TTM) | -3.22 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.23% |
| Nisbah Semasa (MRQ) | 17.66 |
| Aliran Tunai Operasi (OCF TTM) | -196.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -128.49 M |
| Pulangan Atas Aset (ROA TTM) | -22.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Xenon Pharmaceuticals Inc. | Menaik | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.14% |
| % Dimiliki oleh Institusi | 103.51% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Dec 2025 | 5,424,444 |
| Janus Henderson Group Plc | 31 Dec 2025 | 4,084,034 |
| Braidwell Lp | 31 Dec 2025 | 1,825,076 |
| Commodore Capital Lp | 31 Dec 2025 | 1,800,000 |
| Jennison Associates Llc | 31 Dec 2025 | 1,292,055 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 97.00 (Baird, 70.62%) | Beli |
| Median | 71.00 (24.89%) | |
| Rendah | 60.00 (Wolfe Research, 5.54%) | Beli |
| Purata | 74.38 (30.84%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 56.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Deutsche Bank | 10 Mar 2026 | 90.00 (58.31%) | Beli | 60.61 |
| HC Wainwright & Co. | 10 Mar 2026 | 74.00 (30.17%) | Beli | 60.61 |
| Wedbush | 10 Mar 2026 | 64.00 (12.58%) | Beli | 60.61 |
| Wells Fargo | 10 Mar 2026 | 68.00 (19.61%) | Beli | 60.61 |
| 27 Feb 2026 | 49.00 (-13.81%) | Beli | 43.23 | |
| Baird | 09 Mar 2026 | 97.00 (70.62%) | Beli | 62.76 |
| Needham | 09 Mar 2026 | 80.00 (40.72%) | Beli | 62.76 |
| 27 Feb 2026 | 58.00 (2.02%) | Beli | 43.23 | |
| Wolfe Research | 24 Feb 2026 | 60.00 (5.54%) | Beli | 44.79 |
| JP Morgan | 09 Jan 2026 | 62.00 (9.06%) | Beli | 42.15 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |